Article: FDA Approves SINGULAIR For Seasonal Allergic Rhinitis; A New Class of Therapy for the Treatment of Seasonal Allergic Rhinitis -Also Known as Hay Fever-.

Business Editors/Health & Pharmaceutical Writers

NOTE TO MEDIA: Multimedia assets available

A photo is available at URL:

http://www.businesswire.com/cgi-bin/photo.cgi?pw.010203/bb3

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Jan. 2, 2003

Merck & Co., Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the leukotriene blocker SINGULAIR(R) (montelukast sodium) for the relief of symptoms of seasonal allergic rhinitis (also known as hay fever).

A convenient once-a-day tablet, SINGULAIR helps relieve a broad range of seasonal allergy symptoms for 24 hours. SINGULAIR is available to treat ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!